Status:
COMPLETED
Observational Study to Determine How Physicians Make Treatment Decisions in Patients Treated With Tofacitinib for Moderate to Severe Active Rheumatoid Arthritis
Lead Sponsor:
Pfizer
Conditions:
Arthritis, Rheumatoid
Eligibility:
All Genders
18+ years
Brief Summary
This non-interventional study aims to identify key factors that are driving treatment decisions by rheumatologists in the treatment of rheumatoid arthritis (RA) patients starting treatment with Tofaci...
Eligibility Criteria
Inclusion
- Patients aged ≥ 18 years
- Confirmed Diagnosis of Rheumatoid Arthritis by rheumatologist
- Patient is eligible for Tofacitinib treatment according to Summary of Product Characteristics (SmPC)
- Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study.
Exclusion
- Contraindications according to Xeljanz® SmPC
- Receipt of any investigational drug within 3 months before study inclusion
- Patients who have received any previous treatment with Tofacitinib or other JAK inhibitors
- Patients who are investigational site staff members or patients who are Pfizer employees directly involved in the conduct of the study.
Key Trial Info
Start Date :
November 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 17 2023
Estimated Enrollment :
1459 Patients enrolled
Trial Details
Trial ID
NCT03387423
Start Date
November 2 2017
End Date
July 17 2023
Last Update
October 21 2024
Active Locations (91)
Enter a location and click search to find clinical trials sorted by distance.
1
Private Praxis
Düsseldorf, North Rhine-Westphalia, Germany, 40237
2
Private Practice
Zschopau, Saxony, Germany, 09405
3
Private Practice Kupka
Altenburg, Germany, 04600
4
Private Practise Boehm
Altenholz, Germany, 24161